Zooming in on Early Embryonic Development
News May 21, 2012
If there were just one book of biology, it would be rewritten constantly with the sometimes dramatic, more often incremental advances in understanding that come with the nature of science. Constant revision can come with insight – think Darwin – or with technology – witness faster, cheaper sequencing machines – or with both.
New fields give rise to newer ones, such as the slew of -omics that sprang from genomics. Genetics, the study of the basic physical unit of inheritance, has led to epigenetics, the study of chemical compounds that modify the genome, telling it what to do, where to do it, and when to do it.
When Alexander Meissner teaches his epigenetics students about the earliest stages of mammalian development, he uses a textbook model of DNA methylation. Until now. This chapter of basic biology will have to be rewritten, based on research he and Broad colleagues report in Nature showing that methyl groups behave in a more complex pattern than previously understood.
Epigenetic modifications such as DNA methylation are important because these chemical tags enable genes to switch on or off. The classic model says DNA methylation levels in the paternal genome – from sperm – drop sharply just before cell division and the maternal genome – the egg – loses DNA methylation later, over subsequent cleavage divisions. But it’s not that simple.
A high-resolution view of mouse embryogenesis before the blastocyst stage – down to the single bases As, Cs, Ts, or Gs in the genetic code – revealed interesting dynamics and differences in DNA methylation between the paternal and maternal genomes that might have implications for how these genes are regulated during early embryonic development. These differentially methylated genes went beyond known imprinted genes, whose expression is determined by the parent from which they came.
“This paper gives you for the first time a base-resolution view of the complete pre-implantation stages, so you can see which parts of the genome, which genes and which regulatory elements change and to what degree,” says Alex, a senior associate member of the Broad, an assistant professor at Harvard University, and senior author of the paper. “Today's technologies are incredibly sensitive, so you can finally zoom in and view this dynamic phase at high resolution. At the Broad and around the world many groups are busy mapping DNA methylation in every possible cell type to gain insights to when and where methylation is used as a regulatory mark, how it changes in normal development and what are changes that occur in different diseases.”
In cancer, for example, it is known that gain and loss of DNA methylation at particular sites in the genome are involved in the disease. Identifying all of these sites might provide clues for disease prediction as well as insights into disease biology. But before making sense of aberrant changes in diseases, it is critical to understand DNA methylation better across all stages of development.
One map has already been redrawn: a genome-scale DNA methylation map in mouse embryogenesis.
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE
First Successful Gene Therapy Trial Reported for People with Hemophilia ANews
Patients with hemophilia A who received a single infusion of an investigational gene therapy showed improved levels of the essential blood clotting protein FVIII, with 11 of 13 achieving normal or near-normal FVIII levels.READ MORE